CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
NCT05996952: RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 77 | RoW | RC48-ADC | West China Hospital, RemeGen Co., Ltd. | Non-muscle Invasive Bladder Cancer | 08/25 | 08/26 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
